Objective: The aim of this study was to evaluate the maternal and perinatal outcomes of COVID-19 infection during pregnancy. Methods: We performed a retrospective review of medical records of 37 pregnant women with the diagnosis of COVID-19. The clinical characteristics, laboratory results, perinatal and neonatal outcomes were analyzed. Results: The majority of cases with COVID-19 were evaluated as mild (97.3%). None of the women needed intensive care unit or invasive mechanical ventilation and mortality were not observed. The most common symptoms were fever (62.2%) and cough (40.5%). Of all the pregnancies, 5.4% ended with abortion, 2.7% with stillbirth, and 10% of the infants were hospitalized in the neonatal intensive care unit. Neonatal mortality was not observed. Conclusion: In our study, none of the pregnant women with SARS-CoV-2 infection had severe illness. Vertical transmission of SARS-CoV-2 which was possible in several studies is not observed in our patient population.
We enrolled 1489 patients in this study. Overall, 775 (52%) patients were male and a mean age of patients was 38.9 ± 11.1 years. Of these patients, 537 of them were received favipiravir, 545 of them were received hydroxychloroquine and 407 of them were received both favipiravir and hydroxychloroquine. Symptoms improvement on the 14th day of follow-up was 1.8 times higher in the group of patients receiving hydroxychloroquine compared to patients who received favipiravir (p = 0.003). On the 3rd day of followup, PCR negativity rate was higher in patients who received hydroxychloroquine (p = 0.004). Hospitalization rates were similar in patients receiving favipiravir and hydroxychloroquine (p = 0.144). However, in the presence of pneumonia at the time of diagnosis, the hospitalization rate was 6.6 times higher in patients who received favipiravir than those who received hydroxychloroquine.
Conclusion:The subgroups of patients treated with hydroxychloroquine and/or favipiravir did not have similar disease severities in our study. Therefore, further studies with homogeneous patient groups to be arranged prospectively are needed.
Objectives To evaluate the maternal and neonatal outcomes of expected and
unexpected pathologically proven placenta accreta spectrum (PAS) cases in a
single multidisciplinary center.
Material and Methods This was a retrospective cohort study of 92 PAS cases
from January 2011 until September 2021. Only cases with histopathologically
invasive placentation were included in the study. The cases diagnosed at the
time of delivery were defined as unexpected PAS (uPAS) and those diagnosed
antenatally as expected PAS (ePAS). Maternal and neonatal outcomes of both
groups were compared.
Results Thirty-five (38%) of 92 cases were in the uPAS group.
Placenta previa and high-grade PAS (percreata) were significantly higher in the
ePAS group (p=0.028, p<0.001; respectively). The mean packed red
blood cell transfusion was significantly higher in the uPAS group
(p=0.030) but transfusions of other blood products were similar in the
two groups. There was no significant difference in intraoperative complication
rates between the two groups. Preterm delivery (<37 weeks) was
significantly higher in the ePAS group (p<0.001), but there was no
significant difference between the two groups in terms of adverse neonatal
outcomes.
Conclusions Our single center data show that although ePAS cases include
more highly invasive PAS cases, maternal hemorrhagic morbidity is lower than
uPAS cases. Reducing maternal morbidity in PAS cases can be achieved by
increasing antenatal diagnosis.
Bu çalışma ile cerrahi geçirecek hastaların operasyon öncesinde yoğun stres yaşadıkları anlaşılmaktadır. Anestesiztler, hastalar ile ameliyat öncesi riskleri değerlendirmek, yapılacak işlemler hakkında bilgi vermek ve ameliyat öncesi kaygılarını ortadan kaldırmak için görüşmelidir. Hastada operasyon esnasında anksiyetenin yaratabileceği hemodinamik sorunları engellemek ve postoperatif iyileşme sürecini hızlandırmak için sedasyon amaçlı farmakolojik ve nonfarmakolojik metodların da uygulanması gerekmektedir.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.